Glofitamab plus R‐CHOP or polatuzumab vedotin‐R‐CHP is deliverable with high overall response in patients ≤65 years of age with high‐risk DLBCL: Interim analysis of COALITION.

Autor:	Minson, A., Verner, E., Giri, P., Wong, S. M., Ratnasingam, S., Butler, J., Janowski, W., Ku, M., Cheah, C. Y., Hertzberg, M., Herbert, K., Hamad, N., Yannakou, C. K., Neeson, P., Saghebi, J., Blombery, P., Robertson, M., Lau, L. S., Xie, J., Seymour, J. F.
Předmět:	ANTINEOPLASTIC combined chemotherapy protocols DIFFUSE large B-cell lymphomas TERMINATION of treatment COALITIONS BISPECIFIC antibodies
Zdroj:	Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p421-422, 2p
Abstrakt:	B Results: b 47 patients have received >=1 dose of study treatment at Nov 1, 2022 (25 Arm A, 22 Arm B). 42 (89%) have de novo DLBCL and 5 (11%) have transformed indolent lymphoma. Glofitamab plus R-CHOP or polatuzumab vedotin-R-CHP is deliverable with high overall response in patients <=65 years of age with high-risk DLBCL: Interim analysis of COALITION B Background: b Improved treatments are needed for patients (pts) with high-risk (HR) DLBCL. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text